NYSE · CLB

Core Laboratories Inc.

$11.23 -$0.44 (-3.77%) 1D Market open

Key Metrics

$537.95M
Market cap
18.53×
P/E · TTM
$524.73M
Revenue · TTM
$29.03M
Net income
EPS · TTM $0.62
Dividend yield 0.3%
Free cash flow $22.46M
Beta · 1Y 0.91
EBITDA · TTM $57.77M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 24
    From its Feb 3 high, the share price fell 45%.

    Peak close $19.64 on Feb 3; trough close $10.72 on Jun 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -45%
  • Apr 30
    The stock moved -15.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 30

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$537.95M
Enterprise value$629.59M
Shares outstanding46.1M
52-wk range$9.72 – $20.36
Avg volume · 20D464.5K
Net cash −$91.64M
Book value / share$5.75
IndustryOil & Gas Field Services, Nec
ExchangeNYSE
About Core Laboratories Inc.
IPO dateSep 21, 1995
Employees3300

Core Laboratories Inc is a providers of proprietary and patented reservoir description and production enhancement services and products to the oil and gas industry, through client relationships. The company operates its business in two segments; Reservoir Description, and Production Enhancement.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E18.53
P/S1.03
P/FCF23.95
EV/EBITDA10.90
EV/Sales1.20
Graham №$8.96

Profitability

Gross
Operating 8.2%
Net 5.5%
FCF 4.3%
ROE / ROIC 11.1% · 8.2%

Financial Health

Current ratio2.05
Quick ratio1.50
Debt / equity0.43
Debt / EBITDA 1.98
Net cash −$91.64M
Working capital$109.64M

Cash Flow · TTM

Operating CF $34.34M
Capex −$11.87M
Free cash flow $22.46M
Buybacks $14.40M
Dividends paid $1.86M
Shareholder yield 3.0%

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

$8.96 vs $11.23
Trades 1.3× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings